ArticleScientific reports2025
Clinical characteristics and short-term outcomes of pediatric lymphoma: a retrospective cohort study from a large tertiary hospital in a low- and middle-income country.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of childhood cancer has increased, with lymphoma being the third most common malignancy in children and showing improved survival rates. This study aimed to analyse the demographic, clinical, and outcome data of pediatric lymphoma patients, compare the characteristics of the HL and NHL subtypes, and evaluate treatment outcomes. A single-center retrospective cohort study was conducted at An-Najah National University Hospital (NNUH) in Palestine from 2013 to 2023. Seventy-five pediatric patients (≤ 18 years) newly diagnosed with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) were included, and data from electronic medical records were used. Follow-up data were analysed via Kaplan-Meier survival curves to determine event-free survival (EFS) and overall survival (OAS).This study revealed a male predominance in both NHL (1.9:1) and HL (1.3:1) patients, with a mean age of 9 years for NHL patients and 10 years for HL patients. The majority of patients were from the West Bank (56%) or Gaza (44%). NHL patients commonly presented with GI symptoms (31.7%), whereas HL patients (70.6%) presented with neck masses. B symptoms were more common in HL patients (55.9%). The tumor stage also differed, with NHL often being stage III and HL being stage II. The predominant subtypes were Burkitt's lymphoma (BL) for NHL and classical nodular sclerosis for HL. Overall survival was 96%, with 4% mortality. During the follow-up period (mean 26.5 ± 18 months), 84% of the patients had events, with 86.7% of patients remaining event-free. Relapse occurred in 13.3% of patients, predominantly in the NHL group, and the prevalence of OAS was 96%. The 2-year event-free survival (EFS) rate was 85.1%, and the 2-year overall survival (OAS) rate was 96.6%, as estimated via Kaplan‒Meier survival analysis. Our study provides insights into the clinical characteristics and short-term outcomes of pediatric lymphoma patients in Palestine. Pediatric lymphoma is more common in males and primarily affects children over 10 years of age. HL is less prevalent, has a higher survival rate, and most commonly presents with a neck mass. In contrast, NHL is more common, is associated with higher relapse and mortality rates, and often presents with gastrointestinal symptoms. Burkitt's lymphoma (BL) is the most common NHL subtype and is not strongly associated with B symptoms. These findings emphasize the importance of early diagnosis and continuous follow-up in optimizing treatment outcomes. Further studies with larger cohorts and longer follow-up periods are needed to validate these findings and assess long-term survival and cure rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.